{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:32:36Z","timestamp":1795030356453,"version":"4.10.2"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"DOI":"10.1186\/s13054-025-05685-0","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:23:25Z","timestamp":1761564205000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Association between SGLT2 inhibitor use and risk of sepsis-induced cardiomyopathy in patients with type 2 diabetes: a propensity-matched cohort study"],"prefix":"10.1186","volume":"29","author":[{"given":"Jheng-Yan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Jui","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Li","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Chuan","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Min","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"issue":"8","key":"5685_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801\u201310.","journal-title":"JAMA"},{"issue":"4","key":"5685_CR2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/CCM.0000000000002851","volume":"46","author":"SJ Beesley","year":"2018","unstructured":"Beesley SJ, Weber G, Sarge T, Nikravan S, Grissom CK, Lanspa MJ, et al. Septic cardiomyopathy. Crit Care Med. 2018;46(4):625\u201334.","journal-title":"Crit Care Med"},{"key":"5685_CR3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jcrc.2018.12.008","volume":"50","author":"S Vallabhajosyula","year":"2019","unstructured":"Vallabhajosyula S, Geske JB, Kumar M, Kashyap R, Kashani K, Jentzer JC. Doppler-defined pulmonary hypertension in sepsis and septic shock. J Crit Care. 2019;50:201\u20136.","journal-title":"J Crit Care"},{"issue":"1","key":"5685_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jointm.2021.11.004","volume":"2","author":"F Boissier","year":"2022","unstructured":"Boissier F, Aissaoui N. Septic cardiomyopathy: diagnosis and management. J Intensive Med. 2022;2(1):8\u201316.","journal-title":"J Intensive Med"},{"issue":"9","key":"5685_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1177\/08850666231180526","volume":"38","author":"D Hasegawa","year":"2023","unstructured":"Hasegawa D, Ishisaka Y, Maeda T, Prasitlumkum N, Nishida K, Dugar S, et al. Prevalence and prognosis of Sepsis-induced cardiomyopathy: a systematic review and meta-analysis. J Intensive Care Med. 2023;38(9):797\u2013808.","journal-title":"J Intensive Care Med"},{"issue":"1","key":"5685_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13613-022-01089-3","volume":"12","author":"YM Lin","year":"2022","unstructured":"Lin YM, Lee MC, Toh HS, Chang WT, Chen SY, Kuo FH, et al. Association of sepsis-induced cardiomyopathy and mortality: a systematic review and meta-analysis. Ann Intensive Care. 2022;12(1):112.","journal-title":"Ann Intensive Care"},{"key":"5685_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112001","volume":"220","author":"W Lai","year":"2025","unstructured":"Lai W, Liu L, Wang S, Tang Q, Liu Y, Chai Y. The impact of diabetes on sepsis-induced cardiomyopathy. Diabetes Res Clin Pract. 2025;220:112001.","journal-title":"Diabetes Res Clin Pract"},{"issue":"13","key":"5685_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010263","volume":"97","author":"HS Jeong","year":"2018","unstructured":"Jeong HS, Lee TH, Bang CH, Kim JH, Hong SJ. Risk factors and outcomes of sepsis-induced myocardial dysfunction and stress-induced cardiomyopathy in sepsis or septic shock: a comparative retrospective study. Medicine (Baltimore). 2018;97(13):e0263.","journal-title":"Medicine (Baltimore)"},{"issue":"21","key":"5685_CR9","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"12","key":"5685_CR10","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"issue":"10","key":"5685_CR11","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108\u201317.","journal-title":"Diabetologia"},{"issue":"6","key":"5685_CR12","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose Co-Transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5(6):632\u201344.","journal-title":"JACC Basic Transl Sci"},{"issue":"6","key":"5685_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41569-020-00492-2","volume":"18","author":"SM Hollenberg","year":"2021","unstructured":"Hollenberg SM, Singer M. Pathophysiology of sepsis-induced cardiomyopathy. Nat Rev Cardiol. 2021;18(6):424\u201334.","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"5685_CR14","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.3390\/ijms23073587","volume":"23","author":"K Nakamura","year":"2022","unstructured":"Nakamura K, Miyoshi T, Yoshida M, Akagi S, Saito Y, Ejiri K, et al. Pathophysiology and treatment of diabetic cardiomyopathy and heart failure in patients with diabetes mellitus. Int J Mol Sci. 2022;23(7):3587. https:\/\/doi.org\/10.3390\/ijms23073587.","journal-title":"Int J Mol Sci"},{"issue":"9982","key":"5685_CR15","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","volume":"385","author":"F Zannad","year":"2015","unstructured":"Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067\u201376.","journal-title":"Lancet"},{"issue":"10","key":"5685_CR16","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1016\/j.numecd.2021.06.002","volume":"31","author":"E Mannucci","year":"2021","unstructured":"Mannucci E, Nreu B, Montereggi C, Ragghianti B, Gallo M, Giaccari A, et al. Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2021;31(10):2745\u201355.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"15","key":"5685_CR17","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1001\/jama.2015.13480","volume":"314","author":"JS Haukoos","year":"2015","unstructured":"Haukoos JS, Lewis RJ. The propensity score. JAMA. 2015;314(15):1637\u20138.","journal-title":"JAMA"},{"issue":"6","key":"5685_CR18","first-page":"863","volume":"6","author":"AW Bhatti","year":"2024","unstructured":"Bhatti AW, Patel R, Dani SS, Khadke S, Makwana B, Lessey C, et al. SGLT2i and primary prevention of cancer therapy-related cardiac dysfunction in patients with diabetes. JACC: CardioOncology. 2024;6(6):863\u201375.","journal-title":"JACC: CardioOncology"},{"issue":"4","key":"5685_CR19","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268\u201374.","journal-title":"Ann Intern Med"},{"issue":"10354","key":"5685_CR20","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","volume":"400","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757\u201367.","journal-title":"Lancet"},{"issue":"1","key":"5685_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jchf.2023.08.026","volume":"12","author":"V Avula","year":"2024","unstructured":"Avula V, Sharma G, Kosiborod MN, Vaduganathan M, Neilan TG, Lopez T, et al. SGLT2 inhibitor use and risk of clinical events in patients with cancer therapy-related cardiac dysfunction. JACC Heart Fail. 2024;12(1):67\u201378.","journal-title":"JACC Heart Fail"},{"issue":"1","key":"5685_CR22","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","volume":"9","author":"MW Bloom","year":"2016","unstructured":"Bloom MW, Hamo CE, Cardinale D, Ky B, Nohria A, Baer L, et al. Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging. Circ Heart Fail. 2016;9(1):e002661.","journal-title":"Circ Heart Fail"},{"issue":"2","key":"5685_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4266\/acc.2020.00248","volume":"35","author":"R Habimana","year":"2020","unstructured":"Habimana R, Choi I, Cho HJ, Kim D, Lee K, Jeong I. Sepsis-induced cardiac dysfunction: a review of pathophysiology. Acute Crit Care. 2020;35(2):57\u201366.","journal-title":"Acute Crit Care"},{"issue":"9404","key":"5685_CR24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(03)15326-3","volume":"363","author":"N Pathan","year":"2004","unstructured":"Pathan N, Hemingway CA, Alizadeh AA, Stephens AC, Boldrick JC, Oragui EE, et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet. 2004;363(9404):203\u20139.","journal-title":"Lancet"},{"issue":"2","key":"5685_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1006\/jmcc.1997.0592","volume":"30","author":"SE Francis","year":"1998","unstructured":"Francis SE, Holden H, Holt CM, Duff GW. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J Mol Cell Cardiol. 1998;30(2):215\u201323.","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"5685_CR26","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","volume":"11","author":"SR Kim","year":"2020","unstructured":"Kim SR, Lee SG, Kim SH, Kim JH, Choi E, Cho W, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. 2020;11(1):2127.","journal-title":"Nat Commun"},{"issue":"9328","key":"5685_CR27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(02)09459-X","volume":"360","author":"D Brealey","year":"2002","unstructured":"Brealey D, Brand M, Hargreaves I, Heales S, Land J, Smolenski R, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet. 2002;360(9328):219\u201323.","journal-title":"Lancet"},{"issue":"4","key":"5685_CR28","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.bbadis.2018.10.011","volume":"1865","author":"G Stanzani","year":"2019","unstructured":"Stanzani G, Duchen MR, Singer M. The role of mitochondria in sepsis-induced cardiomyopathy. Biochim Biophys Acta Mol Basis Dis. 2019;1865(4):759\u201373.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"Suppl1","key":"5685_CR29","first-page":"A15278","volume":"140","author":"Y Maejima","year":"2019","unstructured":"Maejima Y, Empagliflozin. A SGLT2 inhibitor, directly protects cardiomyocytes by off-target effect-mediated promotion of mitophagy. Circulation. 2019;140(Suppl1):A15278\u2013A.","journal-title":"Circulation"},{"key":"5685_CR30","doi-asserted-by":"publisher","first-page":"859253","DOI":"10.3389\/fcvm.2022.859253","volume":"9","author":"X Li","year":"2022","unstructured":"Li X, Flynn ER, do Carmo JM, Wang Z, da Silva AA, Mouton AJ, et al. Direct cardiac actions of Sodium-glucose cotransporter 2 inhibition improve mitochondrial function and attenuate oxidative stress in pressure overload-induced heart failure. Front Cardiovasc Med. 2022;9:859253.","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"5685_CR31","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/ehf2.12336","volume":"5","author":"J Mustroph","year":"2018","unstructured":"Mustroph J, Wagemann O, L\u00fccht CM, Trum M, Hammer KP, Sag CM, et al. Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes. ESC Heart Fail. 2018;5(4):642\u20138.","journal-title":"ESC Heart Fail"},{"issue":"7","key":"5685_CR32","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.cardfail.2024.10.448","volume":"31","author":"S Khadke","year":"2025","unstructured":"Khadke S, Kumar A, Bhatti A, Dani SS, Al-Kindi S, Nasir K, et al. GLP-1 receptor agonist in nonobese patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction. J Card Fail. 2025;31(7):989\u20131001.","journal-title":"J Card Fail"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-025-05685-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-025-05685-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-025-05685-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T10:02:33Z","timestamp":1764583353000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-025-05685-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5685"],"URL":"https:\/\/doi.org\/10.1186\/s13054-025-05685-0","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Chi Mei Hospital (approval number: 11402-E02). The requirement for informed consent was waived because the study used de-identified, aggregate-level data obtained from the TriNetX research network.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"452"}}